Search details
1.
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Cancer Sci
; 115(4): 1273-1282, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38287788
2.
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
Cancer Sci
; 113(6): 2109-2117, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35377496
3.
Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting.
Br J Cancer
; 126(4): 606-614, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34782748
4.
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.
Lancet Oncol
; 21(6): 843-850, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32502444
5.
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
Int J Clin Oncol
; 24(7): 731-770, 2019 Jul.
Article
in English
| MEDLINE | ID: mdl-31049758
6.
Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer.
Int J Clin Oncol
; 22(1): 59-69, 2017 Feb.
Article
in English
| MEDLINE | ID: mdl-27553958
7.
Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
Int J Clin Oncol
; 22(2): 257-268, 2017 Apr.
Article
in English
| MEDLINE | ID: mdl-27816990
8.
Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.
Cancer Sci
; 107(8): 1117-23, 2016 Aug.
Article
in English
| MEDLINE | ID: mdl-27270784
9.
Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
Invest New Drugs
; 34(5): 596-603, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27363843
10.
Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.
Invest New Drugs
; 33(4): 881-9, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-25924991
11.
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
Invest New Drugs
; 33(3): 641-51, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25809858
12.
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Jpn J Clin Oncol
; 44(9): 835-40, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-25097183
13.
Secondary osteosarcoma developing 10 years after chemoradiotherapy for non-small-cell lung cancer.
Jpn J Clin Oncol
; 44(2): 191-4, 2014 Feb.
Article
in English
| MEDLINE | ID: mdl-24338556
14.
CD133 expression: a potential prognostic marker for non-small cell lung cancers.
Int J Clin Oncol
; 19(2): 254-9, 2014 Apr.
Article
in English
| MEDLINE | ID: mdl-23479121
15.
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.
Lung Cancer
; 191: 107557, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38626709
16.
Expression of Bim, Noxa, and Puma in non-small cell lung cancer.
BMC Cancer
; 12: 286, 2012 Jul 12.
Article
in English
| MEDLINE | ID: mdl-22788963
17.
Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer.
Eur J Cancer
; 160: 227-234, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34862083
18.
A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure.
Respir Med Case Rep
; 32: 101364, 2021.
Article
in English
| MEDLINE | ID: mdl-33665078
19.
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma.
Respir Med Case Rep
; 31: 101170, 2020.
Article
in English
| MEDLINE | ID: mdl-32714828
20.
Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
Lung Cancer
; 128: 20-25, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30642448